Nirmanmoh Bhatia1, Anthony J Voelkel2, Zeeshan Hussain3, Umesh C Sharma4, Mark S Slaughter5, Emma J Birks6, Kelly C McCants6. 1. Division of Cardiovascular Medicine, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States. 2. Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, United States. 3. Department of Internal Medicine, University of Louisville, Louisville, Kentucky, United States. 4. Division of Cardiovascular Medicine, University of Buffalo, Buffalo, New York, United States. 5. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky, United States. 6. Division of Cardiovascular Medicine, University of Louisville, Louisville, Kentucky, United States.
Abstract
BACKGROUND: There is a paucity of data on the use of induction immunosuppression in patients with active infections undergoing orthotopic heart transplantation (OHT). We hypothesized that induction immunosuppression in patients with ventricular assist device (VAD) undergoing OHT with localized active driveline infection (DLI) does not lead to worse outcomes. MATERIALS AND METHODS: We retrospectively analyzed our database for bridge-to-transplant VAD patients who underwent OHT and received induction therapy. Patients were stratified into those with and without active DLI at the time of OHT and followed up till death or at least 30 months after OHT. Posttransplant length of stay (LOS), frequency of infections, and mortality were compared between the two groups. RESULTS: Thirty-eight patients (30 males) with mean age of 57.5 ± 13 years with VAD underwent OHT during the study period. Twelve had active DLI. Mean follow-up was 46.4 ± 23.1 months. In the DLI versus non-DLI group, there was no difference in mortality (17 vs. 23%, p = NS), LOS (16.3 ± 5.4 vs. 17.2 ± 13.7, p = NS), postoperative renal function, incidence of hyperacute or late rejection or infection either in the first month (25 vs. 23%, p = NS) or during entire follow-up (92 vs. 88%, p = NS). No patient in the DLI group had infections attributable to the same organism responsible for pretransplant DLI. CONCLUSION: In patients with active DLI, induction immunosuppression after OHT did not increase LOS, infections, or mortality after at least 30 months of follow-up and therefore it appears to be a safe and feasible therapeutic option. Georg Thieme Verlag KG Stuttgart · New York.
BACKGROUND: There is a paucity of data on the use of induction immunosuppression in patients with active infections undergoing orthotopic heart transplantation (OHT). We hypothesized that induction immunosuppression in patients with ventricular assist device (VAD) undergoing OHT with localized active driveline infection (DLI) does not lead to worse outcomes. MATERIALS AND METHODS: We retrospectively analyzed our database for bridge-to-transplant VAD patients who underwent OHT and received induction therapy. Patients were stratified into those with and without active DLI at the time of OHT and followed up till death or at least 30 months after OHT. Posttransplant length of stay (LOS), frequency of infections, and mortality were compared between the two groups. RESULTS: Thirty-eight patients (30 males) with mean age of 57.5 ± 13 years with VAD underwent OHT during the study period. Twelve had active DLI. Mean follow-up was 46.4 ± 23.1 months. In the DLI versus non-DLI group, there was no difference in mortality (17 vs. 23%, p = NS), LOS (16.3 ± 5.4 vs. 17.2 ± 13.7, p = NS), postoperative renal function, incidence of hyperacute or late rejection or infection either in the first month (25 vs. 23%, p = NS) or during entire follow-up (92 vs. 88%, p = NS). No patient in the DLI group had infections attributable to the same organism responsible for pretransplant DLI. CONCLUSION: In patients with active DLI, induction immunosuppression after OHT did not increase LOS, infections, or mortality after at least 30 months of follow-up and therefore it appears to be a safe and feasible therapeutic option. Georg Thieme Verlag KG Stuttgart · New York.
Authors: J P Borde; G Sitaru; W H Kopp; A Ruhparwar; P Ehlermann; F Lasitschka; A Dalpke; A Heininger Journal: J Cardiothorac Surg Date: 2016-07-11 Impact factor: 1.637
Authors: Jason M Ali; Serena Patel; Pedro Catarino; Alain Vuylsteke; Stephen Pettit; Sai Bhagra; Anna Kydd; Clive Lewis; Jayan Parameshwar; Pradeep Kaul; Catherine Sudarshan; Steven Tsui; David Jenkins; Yasir Abu-Omar; Marius Berman Journal: J Thorac Dis Date: 2020-05 Impact factor: 2.895